Havas ECS is a strategic education and regulatory-compliant communications and commercialization agency focused on products and technologies targeting the endocannabinoid system. As an evidence-based foundation to our business, Havas ECS offers the only online program for earning a Certificate in Endocannabinoid Medicine (CECM), as an accredited medical education activity of the American Journal of Endocannabinoid Medicine.
The Havas ECS medical education content is also available to industry for customized application in training of employees, customers, executive and medical staff, community referring clinicians and pharmacists, and in support of investor relations, medical speaker programs, corporate communications, and regulatory compliant brand communications.
Santé Cannabis operates at the intersection of clinical practice and R&D. We’re one of the foremost medical clinics in Canada, dedicated to cannabinoid treatments, with four locations across Quebec and a team of healthcare professionals that include family physicians, specialists in chronic pain, cancer, gastroenterology, and endocrinology. We’re also a leading contract research organization that offers clients a full range of services, including training opportunities, product development, regulatory support and patient recruitment for both observational and interventional trials.
KinetoChem LLC is a US-based company which manufactures high purity synthetic cannabinoids for all stages of research. We offer Active Pharmaceutical Ingredients (APIs) for pre-clinical, clinical, and consumer goods with various quantities available (milligram, gram, and kilogram). Our facility and manufacturing processes meet all state and federal regulatory requirements including DEA Schedule I licensing for Analysis, Bulk Manufacturing, and Export.
As the first R&D cannabis company in Latin America, Entourage Phytolab has a strong branding and reputation in largest pharmaceutical market in the region, Brazil. It has developed a state-of-the art extraction and innovative formulations that will be used in its five drugs pipeline. Its first drug, a full spectrum CBD formulation for epilepsy with improved bioavailability, is scheduled to begin sales in Brazilian pharmacies in early 2021 and to get its full register in 2022.